title: Duloxetine as an SNRI treatment for generalized anxiety disorder: results from a placebo and active-controlled trial.
abstract: This study examined the efficacy and tolerability of duloxetine 60-120 mg/day for the treatment of patients with generalized anxiety disorder. This was a multicenter, randomized, double-blind, flexible-dose, placebo and active-controlled (venlafaxine extended-release 75-225 mg/day) trial designed to assess duloxetine 60-120 mg/day during 10 weeks of treatment in adults with Diagnostic and statistical manual of mental disorders-IV-defined generalized anxiety disorder. The primary efficacy outcome measure was mean change from baseline to endpoint in the Hamilton Anxiety Rating Scale total score assessed using analysis of covariance. A total of 487 patients were randomly assigned to duloxetine (n=162), venlafaxine XR (n=164), or placebo (n=161). Significantly greater improvement on the Hamilton Anxiety Rating Scale total score occurred in the duloxetine (P=0.007) and venlafaxine XR (P<0.001) groups compared with the placebo group. Overall discontinuation rates did not differ among the three groups, but adverse event-related discontinuation was significantly higher in the duloxetine (14.2%, P<0.001) and venlafaxine XR (11.0%, P=0.001) groups than in the placebo group (1.9%). During the 2-week drug-tapering phase, discontinuation-emergent adverse events were significantly greater in the venlafaxine XR group (26.9%, P=0.04), but not in the duloxetine group (19.4%, P=0.448) compared with placebo (15.8%). Duloxetine 60-120 mg/day and venlafaxine XR 75-225 mg/day were each efficacious treatments for patients with generalized anxiety disorder.
authors.affiliation: Community Research, Cincinnati, Ohio 45227, USA. jhartford@communityresearch.com
authors.forename: James
authors.initials: J
authors.lastname: Hartford
authors.forename: Susan
authors.initials: S
authors.lastname: Kornstein
authors.forename: Michael
authors.initials: M
authors.lastname: Liebowitz
authors.forename: Teresa
authors.initials: T
authors.lastname: Pigott
authors.forename: James
authors.initials: J
authors.lastname: Russell
authors.forename: Michael
authors.initials: M
authors.lastname: Detke
authors.forename: Daniel
authors.initials: D
authors.lastname: Walker
authors.forename: Susan
authors.initials: S
authors.lastname: Ball
authors.forename: Eduardo
authors.initials: E
authors.lastname: Dunayevich
authors.forename: Jeff
authors.initials: J
authors.lastname: Dinkel
authors.forename: Janelle
authors.initials: J
authors.lastname: Erickson
mesh_terms: D000328:Adult; D001008:Anxiety Disorders / Q000175:diagnosis / Q000188:drug therapy* / Q000523:psychology; D003511:Cyclohexanols / Q000009:adverse effects / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D000068736:Duloxetine Hydrochloride; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010555:Personality Inventory; D017367:Selective Serotonin Reuptake Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D013375:Substance Withdrawal Syndrome / Q000209:etiology; D013876:Thiophenes / Q000009:adverse effects / Q000627:therapeutic use*; D016896:Treatment Outcome; D000069470:Venlafaxine Hydrochloride
chemical_list: D003511:Cyclohexanols; D000068736:Duloxetine Hydrochloride; D017367:Selective Serotonin Reuptake Inhibitors; D013876:Thiophenes; D000069470:Venlafaxine Hydrochloride